Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01696032 · ClinicalTrials.gov registry record · Phase 2
SGI-110 in Combination With Carboplatin in Ovarian Cancer
A Phase 2 study, sponsored by Astex Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 120
- Enrollment target
NCT01696032 is a Phase 2 study that has completed, run by Astex Pharmaceuticals. The registered enrollment target is 120 participants.
The verdict
NCT01696032, a Phase 2 study, has completed, sponsored by Astex Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 120 participants
- Enrollment target
Study Summary
A 2-part, Phase 2 controlled, open-label, randomized study in participants with platinum-resistant recurrent ovarian cancer. In Part 1, participants received SGI-110 and carboplatin. The optimum dose of SGI-110 (guadecitabine) was identified in Part 1 based on safety and efficacy. In Part 2, participants were randomized to receive the dose identified in Part 1 plus carboplatin or one of four treatment of choice at the discretion of the investigator. The treatment of choice consisted of topotecan, pegylated liposomal doxorubicin, paclitaxel or gemcitabine.
Interventions
- DRUG Carboplatin
- DRUG SGI-110
- DRUG Treatment of Choice (topotecan, pegylated liposomal doxorubicin, paclitaxel, or gemcitabine)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 120 participants |
| Start Date | 2012-09 |
| Est. Completion | 2016-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01696032
The ClinicalTrials.gov registry entry for NCT01696032 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 120 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Astex Pharmaceuticals, which has 38 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Carboplatin is the first listed.
NCT01696032 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01696032 about?
NCT01696032 is a clinical study titled "SGI-110 in Combination With Carboplatin in Ovarian Cancer". A 2-part, Phase 2 controlled, open-label, randomized study in participants with platinum-resistant recurrent ovarian cancer. In Part 1, participants received SGI-110 and carboplatin. The optimum dose of SGI-110 (guadecitabine) was identified in Part 1 based on safety and efficacy. In Part 2, partici...
What is the current status of trial NCT01696032?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 120 participants. The study started on 2012-09. Estimated completion is 2016-08.
What interventions are being tested in trial NCT01696032?
The interventions under investigation include: Carboplatin (DRUG), SGI-110 (DRUG), Treatment of Choice (topotecan, pegylated liposomal doxorubicin, paclitaxel, or gemcitabine) (DRUG).
Who is sponsoring clinical trial NCT01696032?
This trial is sponsored by Astex Pharmaceuticals, which has 38 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.